Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
Silence Therapeutics announced an oral presentation on its SANRECO Phase 2 study of divesiran for polycythemia vera at ASH 2026. The presentation, by Marina Kremyanskaya, is scheduled for December 14, 2026. Silence Therapeutics is a clinical-stage biotech company focused on siRNA-based therapies.
How this was made
The 30-second read
Why it matters
The Phase 2 data will be the first substantive efficacy readout for divesiran, shaping future development and valuation.
Market read
New trial data could trigger significant price movement for SLN and affect peer biotech valuations.
What to watch
Regulatory pathway and competitive landscape for polycythemia vera therapies.
Background
Silence Therapeutics is a clinical‑stage biotech developing siRNA medicines; the company uses its mRNAi GOLD™ platform.
Ticker impact
Silence Therapeutics will present Phase 2 data on its divesiran trial for polycythemia vera at ASH 2026.
potential upside if data are positive, downside risk if results disappoint
Phase 2 data are material for a clinical‑stage biotech; first disclosure of trial results typically drives price volatility.
Market effects
May influence sentiment toward other siRNA and rare‑disease biotech firms.
Limited to markets where Silence Therapeutics trades (US and UK).
Low; impact confined to biotech sector investors.
Counterpoint
If the trial fails, the stock could see a sharp sell‑off despite hype.
Key entities
- personMarina Kremyanskaya
Presenting author, MD PhD, Icahn School of Medicine at Mount Sinai.
- companySilence Therapeutics plc
Clinical‑stage biotech developing siRNA therapeutics.
